tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Q32 Bio Sells ADX-097 to Akebia Therapeutics
PremiumCompany AnnouncementsQ32 Bio Sells ADX-097 to Akebia Therapeutics
3M ago
Akebia Therapeutics announces establishment of rare kidney disease pipeline
Premium
The Fly
Akebia Therapeutics announces establishment of rare kidney disease pipeline
3M ago
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
Premium
The Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
3M ago
Q32 Bio completes enrollment in Part B of SIGNAL-AA trial
PremiumThe FlyQ32 Bio completes enrollment in Part B of SIGNAL-AA trial
4M ago
Q32 Bio Inc.’s Promising Alopecia Areata Treatment Trial Update
Premium
Company Announcements
Q32 Bio Inc.’s Promising Alopecia Areata Treatment Trial Update
5M ago
Eight option delistings on August 18th
Premium
The Fly
Eight option delistings on August 18th
6M ago
Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary
PremiumThe FlyOxford Biomedica completes acquisition of remaining stake in U.S. subsidiary
8M ago
Q32 Bio Stockholders Approve Key Proposals at Annual Meeting
Premium
Company Announcements
Q32 Bio Stockholders Approve Key Proposals at Annual Meeting
8M ago
Q32 Bio Inc. Reports Q1 2025 Financial Results
Premium
Company Announcements
Q32 Bio Inc. Reports Q1 2025 Financial Results
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100